Scarica l'app Stockscreener
3.35
9.48%
0.29
Dopo l'orario di chiusura:
3.50
0.15
+4.48%
Heartsciences Inc Borsa (HSCS) Ultime notizie
Why HeartSciences Inc. Equity Warrant stock appeals to dividend seekersJuly 2025 News Drivers & Scalable Portfolio Growth Methods - ulpravda.ru
What hedge fund activity signals for HeartSciences Inc. Equity Warrant stockJuly 2025 Chart Watch & Verified Stock Trade Ideas - ulpravda.ru
Will HeartSciences Inc. stock recover faster than peers2025 Sector Review & Momentum Based Trading Signals - ulpravda.ru
Is HeartSciences Inc. stock a safe haven asset2025 Volatility Report & Fast Gaining Stock Reports - ulpravda.ru
Buyout Rumor: Why HeartSciences Inc. Equity Warrant stock remains resilientJuly 2025 Chart Watch & High Conviction Buy Zone Picks - ulpravda.ru
Is HeartSciences Inc. Equity Warrant stock a top pick in earnings seasonPortfolio Allocation Tips & Target Triple-Digit Stock Opportunities - ulpravda.ru
Is HeartSciences Inc. Equity Warrant stock supported by strong cash flows2026 world cup usa national team group stage defensive leaders transition play odds analysis expert opinion - ulpravda.ru
What analysts say about HeartSciences Inc Equity Warrant stockMarket Depth Overview & Free Technical Analysis and Insights - earlytimes.in
Market Meltdown the Virus and our ActionablesStock Price Divergence & Affordable Trading Strategies - bollywoodhelpline.com
Indo Count Industries Limited (ICIL) Expands into New MarketPrice-to-Book Ratio Updates & Exceptional Capital Growth - bollywoodhelpline.com
HeartSciences (NASDAQ:HSCS) Price Target Raised to $9.20 at Ascendiant Capital Markets - Defense World
HeartSciences (NASDAQ:HSCS) and Movano (NASDAQ:MOVE) Critical Survey - Defense World
Why HeartSciences Inc. Equity Warrant stock remains resilient2025 Momentum Check & AI Forecasted Stock Moves - DonanımHaber
Ascendiant Capital Maintains HeartSciences (HSCS) Buy Recommendation - Nasdaq
HeartSciences (HSCS) Receives Updated Analyst Rating and Price T - GuruFocus
HeartSciences (NASDAQ:HSCS) & Health Catalyst (NASDAQ:HCAT) Critical Analysis - Defense World
Does HeartSciences Inc. stock trade at a discount to peersJuly 2025 Spike Watch & Verified Swing Trading Watchlists - Улправда
Why HeartSciences Inc. Equity Warrant stock could see breakout soon2025 Sector Review & Fast Entry High Yield Tips - Улправда
Will HeartSciences Inc. Equity Warrant stock attract ESG investorsMarket Weekly Review & Long Hold Capital Preservation Plans - Улправда
Will HeartSciences Inc. Equity Warrant stock recover faster than peersJuly 2025 Final Week & Growth Focused Stock Pick Reports - DonanımHaber
Will HeartSciences Inc. Equity Warrant stock deliver shareholder valueJuly 2025 Price Swings & Advanced Swing Trade Entry Plans - Улправда
History Review: Does HeartSciences Inc. stock trade at a discount to peers2025 Major Catalysts & Real-Time Volume Triggers - Улправда
HeartSciences Submits MyoVista wavECG Device for FDA Clearance - Diagnostic and Interventional Cardiology
HeartSciences approves indemnification agreements for directors and officers By Investing.com - Investing.com Nigeria
HeartSciences approves indemnification agreements for directors and officers - Investing.com
Heart Test Laboratories Approves Indemnification Agreement - TipRanks
HeartSciences reports no meaningful revenue in Q2 2026 - Medical Buyer
HeartSciences Inc. Reports Second Quarter Fiscal 2026 Financial Results and Progress on MyoVista Insights and wavECG Device Submissions - Quiver Quantitative
HeartSciences (Nasdaq: HSCS) Q2 shows $2M cash, MyoVista Insights push - Stock Titan
HeartSciences (NASDAQ: HSCS) posts loss, highlights going concern and new funding - Stock Titan
HeartSciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2025 - marketscreener.com
HeartSciences files FDA 510(k) for MyoVista WaveCG device - marketscreener.com
HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device - The Manila Times
HeartSciences (Nasdaq: HSCS) separates device, AI-ECG FDA paths - Stock Titan
HeartSciences Inc. Announces Commercial Release of MyoVista Insights™ Version 1.1 Enhancing ECG System Capabilities - Quiver Quantitative
HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with ... - Enidnews.com
HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1 - The Manila Times
HeartSciences Announces Major Upgrade to User Features of - GlobeNewswire
Gross profit of HeartSciences Inc. from 2021 to 2024 - Statista
HeartSciences (HSCS) to Release Quarterly Earnings on Monday - Defense World
Reviewing Hims & Hers Health (NYSE:HIMS) and HeartSciences (NASDAQ:HSCS) - Defense World
S&P 500, NASDAQ and Dow continue upward trend as Wall Street rises to the edge of its all-time high; Treas - The Economic Times
Risk Off: Why MLPR stock is seen as undervaluedPrice Action & Expert-Curated Trade Recommendations - BỘ NỘI VỤ
How HeartSciences Inc. Equity Warrant stock performs in rate cut cyclesJuly 2025 Levels & Weekly Return Optimization Alerts - Newser
HeartSciences (HSCSW) Stock Analysis Report | Financials & Insights - Benzinga
Will HeartSciences Inc. Equity Warrant stock keep outperforming rivalsJuly 2025 Momentum & Reliable Intraday Trade Alerts - Newser
How HeartSciences Inc. stock performs after earningsJuly 2025 Analyst Calls & Low Risk High Reward Ideas - Newser
HeartSciences (HSCS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
CapEx per share of HeartSciences Inc. Warrant 2022- on Heart Test Lab Rg – NASDAQ:HSCSW - TradingView
2.10%
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):